PTPRC and prostate cancer: In line with previous results demonstrating that CD133+ CTCs predicted poor progression-free survival in patients with metastatic castration‐sensitive prostate cancer [19], our results stated worse recurrence-free survival for patients when we considered CD133+ cytokeratin+ CD45− in comparison to cytokeratin+ CD45− CTCs.